As loss-of-function mutations in LIPA result in increased atherosclerosis in humans and overexpression of LIPA reduces atherosclerosis in mouse, the common CAD-associated variants in LIPA might be expected to cause a reduction in the levels of active LAL. Here, LIPA is linked to coronary artery disorder.